UNIVERSITY OF BRISTOL
New University spin-out company

Bristol University announced on 3 May the latest company to spin-out from University research. NeuroTargets Ltd is an innovative biopharmaceutical company based in Bristol and is a joint venture between the University and Progeny bioVentures.

NeuroTargets is utilising state-of-the-art gene technologies to identify and develop novel drug targets for diseases associated with chronic pain, such as rheumatoid arthritis and neuropathic pain associated with diabetes and trauma.

The pioneering research is led by David Wynick, Professor of Molecular Medicine at Bristol University and Consultant Physician at the Bristol Royal Infirmary. Professor Wynick is developing additional gene libraries for the identification of gene targets in a range of other areas, including nerve regeneration, inflammation and stroke disorders.

Commenting on the spin-out, Professor Wynick, said: 'This spin-out is excellent news for the University. It justifies the confidence and support shown in our research by the pharmaceutical industry.'

Dr Neil Bradshaw, Director of the University's Bristol Enterprise Centre, added: 'This is the newest company to be spun-out from the University's research and a further example in a long line of partnerships between the University and the business community, locally, nationally and internationally.'

Previous stories:

Back to archive

Email: public-relations@bristol.ac.uk
Copyright: 2001 The University of Bristol, UK
Updated: Friday, 11-May-2001 12:47:31 BST